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Context: The steroidogenic enzyme aromatase (CYP19A1) is required for estrogen biosynthesis from 
androgen precursors in the ovary and extragonadal tissues. The role of aromatase, and thus estrogens, 
is best illustrated by genetic variations of the CYP19A1 gene leading to aromatase deficiency or excess.
Objective: The objective of this work is to characterize novel CYP19A1 variants.
Design, setting, and patients: Variants causing aromatase deficiency were suspected in four 46,XX 
children of African and Indian origin by careful clinical phenotyping. Sequencing of the CYP19A1 
gene identified novel variants. Minigene experiments, aromatase activity assay, and computational, 
and histological analysis were used to characterize the variants.
Main outcome measure and results: CYP19A1 variants were found in all patients: a deletion in 
intron 9 leading to p.P423_H503del, a delins variant at p.P154, and point variants p.V161D, p.R264C, 
p.R375C. Except for R264C, all variants showed a loss of function. Protein structure and dynamics 
studies were in line with functional assays. The 2 female patients with delins variants manifested 
with ambiguous genitalia at birth. Histologic investigation revealed normal ovarian tissue on one side 
and a streak gonad on the other. Two female patients presented with abnormal pubertal development 
and polycystic ovaries.
Conclusion:  In girls, aromatase deficiency usually manifests at birth, but diagnosis may also be 
made because of abnormal pubertal development or ovarian torsion due to (poly)cystic ovaries. The 
ovary harboring CYP19A1 variants may present as streak gonad or appears normal at birth, but is 
then at very high risk to produce cysts with aging and is therefore prone to ovarian torsion.
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The CYP19A1 gene encodes the steroidogenic enzyme aromatase on chromosome 15q21.2 
(OMIM 107910; RefSeq NM_000103.3). It spans over 123 kb and consists of 9 coding exons 
(spanning over 30 kb, exons 2-10). For the CYP19A1 gene, a large number of alternative 
first exons and 9 different transcriptional start sites with individual promoters have been 
described [1, 2]. Several tissues use their specific promoters leading to a very complex 
tissue-specific regulation of CYP19A1 expression. Metabolic activities of aromatase include 
the biosynthesis of estrone from androstenedione, estriol from 16-hydroxytestosterone, 
and 17β-estradiol from testosterone [3]. Of these, androstenedione and testosterone 
are the common physiological steroid substrates of aromatase [3-5]. Recently 16β-OH-
androstenedione was also reported to be a substrate for aromatase [6]. Although the human 
ovary is the principal site of estrogen production, even the testis produces estrogens, and 
extragonadal synthesis occurs from circulating C19 steroids in bone, breast, brain, ad-
ipose, and other tissues through aromatase expressed in these tissues. The role of aro-
matase and thus estrogens for human biology is best illustrated in disease states, both 
deficiency and excess.
Aromatase deficiency (OMIM 613546)  is a rare, autosomal recessive disorder 
that was first described in 1991 by Shozu et al in a mother who experienced virilisation 
during pregnancy due to a 46,XX fetus with aromatase deficiency that presented with 
severe virilization of the external genitalia at birth [7]. Meanwhile, about 50 cases of 
aromatase deficiency due to variants in CYP19A1 have been reported, both in female 
and male patients (Table 1 and Fig.1) [7-42]. During pregnancy, aromatase deficiency 
of the fetus typically manifests in the pregnant mother by progressive virilization due 
to the inability of the placenta to aromatize androgens derived from the fetal adrenals. 
These androgens also virilize the 46,XX fetus. During infancy and childhood, aroma-
tase deficiency may go unnoticed, although, in some girls, abdominal problems may be 
seen due to ovarian cysts caused by a lack of  feedback regulation of estrogens to the 
hypothalamic-pituitary-gonadal axis [34]. At puberty, girls without aromatase activity 
are not able to produce estrogens from androgen precursors for pubertal development, 
for example, breast and uterine  development. Young men with aromatase deficiency 
usually present in the second decade of life with low bone mass and unfused epiphyses 
leading to  persistent growth into  adulthood with extremely tall stature [43]. In addi-
tion, aromatase  deficiency is reported to cause disturbances of the lipid profile and 
insulin sensitivity (eg,  metabolic syndrome), and it may also cause male infertility and 
affect bone quality.
Aromatase excess (OMIM 139300) has been found in a few, mostly familial cases of gyn-
ecomastia associated with accelerated growth and bone maturation due to excessive pe-
ripheral estrogen production. The main causes of aromatase excess include chromosomal 
rearrangements altering regulatory elements of the CYP19A1 gene expression or a higher 
expression of an alternative first exon enhancing CYP19A1 transcription [44, 45]. By con-
trast, aromatase deficiency is almost exclusively caused by variants altering the coding se-
quence of the CYP19A1 gene, such as point mutations, deletions, and insertions, or splicing 
mutations (Table 1 and Fig. 1).
In this study, we describe several novel variants in CYP19A1. A homozygote splice-
site deletion in the CYP19A1 gene was found in an African 46,XX neonate presenting 
with typical clinical manifestations during pregnancy and at birth. An indel variant in 
exon 5, together with the c.–41C>T variant  in the CYP19A1 promoter that had been 
described earlier, was found in an Indian 46,XX child presenting with an unsolved dis-
order of sex development at age 3 years. Novel point variants were identified in 2 more 
unrelated adolescent girls in India who presented with poor breast development and 
polycystic ovaries. To address the impact of the novel CYP19A1 variants manifesting 
at different time points of sex development and originating from diverse populations, 
we performed genetic, functional, and structural studies and compared the findings of 
novel variants in the CYP19A1 gene with the published literature.
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1. Case Reports, Materials, and Methods
A. Case Reports
Family 1. An 8-day-old newborn was referred to the clinic of A.L. for assessment of ambig-
uous genitalia. The infant was the seventh child of second-degree consanguineous African 
parents. The first child was stillborn (Fig. 2). There was maternal virilization during the 
second pregnancy and the newborn who was declared “male,” died on the first day of life 
(with no further details available). After delivery, signs of virilization slowly decreased in 
the mother, and she subsequently gave birth to 4 healthy sons without suffering from virili-
zation again during these pregnancies. However, during the seventh pregnancy, the mother, 
age 36 years, again developed progressive signs of virilization from 12th week of gestation, 
with  facial and abdominal hirsutism, facial acne, clitoral hypertrophy, and deepening of 
the voice. No drugs or environmental toxins were suspected of influencing the pregnancy. 
Biochemical workup of the mother revealed marked hyperandrogenism with high testos-
terone levels (eg, 45.1 nmol/L at 32/40 weeks of pregnancy, normal range is 2.2-10.7 nmol/L). 
Ultrasound and magnetic resonance imaging studies after delivery revealed enlarged 
ovaries containing multiple follicles consistent with polycystic ovaries. However, the signs 
of virilization decreased slowly after birth, and serum testosterone levels normalized within 
1 month.
The baby was born at term by spontaneous vaginal delivery. Birth weight, length, 
and head circumference were normal (3500  g/50  cm/35  cm). Neonatal adaptation was 
also normal, but the baby had ambiguous genitalia without presenting other dysmorphic 
features. Genital examination showed a 1.5 cm cliterophallus with a single meatus opening 
at the base of the genital tubercle and a complete posterior labial fusion (Prader IV). The 
genital folds were scrotalized, and no gonads were palpable (Fig.  3). Pelvic ultrasound 
showed a uterus, whereas the gonads were not visible. Karyotype was 46,XX. Biochemical 
workup revealed normal electrolytes, 17α-hydroxyprogesterone, cortisol, and renin levels, 
ruling out classic 21-hydroxylase deficiency with congenital adrenal hyperplasia (CAH) 
(Table 2). Testosterone levels were slightly elevated at birth but decreased to normal levels 
by 1 month, whereas other androgen levels were within reference ranges. Estradiol levels 
were very low (Table 2). Follow-up revealed that the patient did not have any distress as 
Figure 1. Localization of reported CYP19A1 variants. The coding exons 2 to 10 and the al-
ternative exon I.1 of the aromatase CYP19A1 gene are shown.
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seen in cortisol deficiency. Thus virilization of the 46,XX baby with concurrent virilization 
of the mother during pregnancy suggested aromatase deficiency in the child.
Patient 2. This 46,XX infant was referred to the clinic of V.P.P.  for workup of am-
biguous genitalia at age 3 years. She was the only child of nonconsanguineous Indian 
parents and was noted to have a phallic structure with absent gonads at birth. There 
was no history of maternal virilization or hirsutism during pregnancy. Evaluation else-
where had ruled out CAH. Karyotype was 46,XX, and laparoscopy had been performed 
at age 8 months and revealed a uterus and fallopian tubes. Unilateral gonad biopsy was 
suggestive of ovarian tissue. At age 3 years, she presented with a well-formed phallus 
with a single opening at the tip with good prepucial skin and fused labioscrotal folds with 
rugosity (Prader IV). Gonads were not palpable. Biochemical workup revealed normal 
cortisol response to an adrenocorticotropin stimulation test (60 minutes, 745 nmol/L), 
normal 17-hydroxyprogesterone, undetectable testosterone, elevated follicle-stimulating 
hormone (FSH), and prepubertal luteinizing hormone (LH) (Table 2). A 100 cell count 
karyotype was repeated, which again revealed only 46,XX cell lines. Laparoscopy was 
also repeated and confirmed earlier findings; gonadal biopsy from the other side revealed 
primordial follicles with ovarian stroma. Because of normal stimulated serum cortisol 
and 17-hydroxyprogesterone, P450 oxidoreductase deficiency (PORD) was considered 
less likely and aromatase deficiency was suspected.
Patient 3. Patient 3, from India, presented at age 14 years with an acute abdomen due to 
ovarian torsion. She was the second child of consanguineous parents (Fig. 2). Past medical 
history was suggestive for some maternal virilization during pregnancy, but at birth, the 
girl was recorded to be healthy, although retrospectively the prominence of the clitoris was 
present since birth. Pubertal development started at around age 11 years with pubic and 
axillary hair, and voice change was noted; breast development started after age 12.5 years, 
and growth of facial hair in the past 6 months was noted. Physical exam revealed a weight 
of 40.6  kg (P10), height 160  cm (P50), blood pressure 90/50  mm  Hg, Ferriman Gallway 
Score 4, and Tanner stage B3/P4/A3. Exam of the external genitalia revealed a slightly 
enlarged clitoris (> 1 cm). Biochemical workup showed elevated LH, FSH, and testosterone 
with rather low estradiol (Table 2). Ultrasound and laparoscopy revealed polycystic ovaries 
on both sides with torsion of the left ovary.
Figure 2. Genetic characterization of 4 patients harboring novel CYP19A1 variants. A, Family 
pedigrees show consanguinity in 3 families. B, Diagram showing localization and specific vari-
ations in the CYP19A1 gene with respect to exon-intron boundaries. Black-filled exon rectangles 
show exons that are translated into RNA/protein sequences despite the genetic variations.
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Patient 4. Patient 4, from India, born to consanguineous parents, presented at age 
14 years for abdominal pain and oligomenorrhea. No maternal virilization was reported 
during pregnancy. The girl likely had atypical genitalia at birth, but this was not recorded. 
Pubertal development started at around age 10 to 11  years with menarche at around 
12 years. Breast development was poor, and clitoromegaly was claimed. At presentation, 
her weight was 50 kg (P50), height 155 cm (P25), and blood pressure was 90/60 mm Hg. No 
skeletal anomalies were found, and Tanner stage was B3P4A3. The genital exam showed a 
clitoromegaly of 20 mm, a common urogenital sinus, and posterior labial fusion. Ultrasound 
and magnetic resonance imaging revealed enlarged polycystic ovaries (Fig. 3). Laboratory 
findings were abnormal for elevated LH, FSH, and testosterone, whereas estradiol was not 
detectable (Table 2).
B. Genetic Studies
Genetic studies of rare steroid disorders were approved by the cantonal ethics’ commission 
of Bern, Switzerland. Written informed consent for the genetic studies was obtained from 
parents and teenage minors. DNA was extracted from blood samples of the patient and both 
parents as available. The CYP19A1 gene (NM_000103.3 or NG_007982.1) was sequenced 
from genomic DNA using a candidate exon-by-exon approach, as previously described [1]. 
Additional primers were used to characterize the deletion found at the boundary of exon/in-
tron 9 and the deletion/insertion in exon 5; these primer sequences are available on request.
For the minigene experiment for genetic workup of patient 1, the wild-type (wt) and 
variant genomic CYP19A1 sequence comprising exon 9 to exon 10 – 3’UTR was cloned in a 
pcDNA3.1 vector. These vectors were then transiently transfected in HEK293 cells using 
Lipofectamine 2000 (Invitrogen AG, Life Technologies). Forty-eight hours after transfection, 
Figure 3. Phenotype of girls with CYP19A1 mutations. A, Picture of the ambiguous genitalia 
at birth found in the 46,XX disorder of sex development index patient 1. Note the phallus-
like tubercle with a single meatus opening at the base and the complete labioscrotal fusion 
(Prader IV). The photograph is shown with the permission of the parents. B, Magnetic reson-
ance imaging of the pelvis in patient 4 at age 14 years showing a large, multiloculated, cystic 
mass (6.8 × 9.6 × 6.5 cm) involving bilateral adnexa (*), displacing the uterus (#) anteriorly 
and inferiorly. Few of the cysts are showing hemorrhage. Both ovaries cannot be separately 
visualized.
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total RNA was extracted and reverse transcribed. Finally, transcripts of wt and variant 
vectors were polymerase chain reaction amplified. Polymerase chain reaction products were 
run on an agarose gel and visualized, as well as subjected to direct sequencing (Microsynth 
AG).
C. Analysis of Conservation of Amino Acids of CYP19A1
We used ConSurf analysis to study the evolutionary conservation of amino acids (aa) in 
CYP19A1 based on structural and phylogenetic relationships between the sequences from 
different species [46, 47]. All CYP19A1 sequences in the Uniprot database were searched, 
and the best quality sequences based on 3 rounds of iterated Phi-BLAST search were kept 
for further analysis. Multiple-sequence alignment of selected sequences was made to com-
pare the position of variants described in this report with aa located at those positions in 
different species (Figs. 4 and 5).
D. CYP19A1 Protein Structure Modeling
In silico mutagenesis of the 3-dimensional protein models of CYP19A1, according to the 
variations identified in the patients, were performed as described earlier [1] using the 3- 
dimensional x-ray crystal structure of human aromatase (3S79) obtained from the Protein 
Data Bank database [48]. Model building was performed with programs YASARA [49] and 
WHATIF [50]. A screening of rotamer libraries was used to minimize stearic clashes with 
the neighboring residues that resulted from the substitution of aa. Molecular dynamics 
(MD) simulations were used to optimize the aa side chains. The final model was refined by 
a 1000 ps MD simulation using the AMBER ff15ipq forcefield [51]. Structure models were 
drawn using the software Pymol (www.pymol.org), and rendering of images was performed 
with POVRAY (www.povray.org).
E. Predicting the Effect of Protein Stability Using Site-Directed Mutator
The site-directed mutator (SDM) tool [52] described by Topham and colleagues [53] was 
used for predicting the effect of CYP19A1 variants. SDM software uses environment-specific 
substitution frequencies within homologous protein families to calculate a stability score. 
The structures of variants used for analysis were generated using the built-in program 
ANDANTE [54]. SDM provides a pseudo-δ G score for stability prediction and also a poten-
tial impact of genetic variants for causing disease.
F. In vitro Functional Testing of CYP19A1 Variants
The human wt CYP19A1 complementary DNA (cDNA) expression vector was described 
previously [1]. The new deletion constructs were created according to the cDNA sequences 
identified by the genetic analysis and minigene experiments. For point mutations, site-
directed mutagenesis was performed to obtain the specific cDNA variants. HEK293 cells were 
transiently transfected with wt and variant CYP19A1 vectors for 48 hours (Lipofectamine 
2000). Aromatase activity was then measured by the tritiated water release assay using cold/
hot androstenedione as substrate (10 nM/[1β-3H(N)]-androstene-3,17-dione; 20 000 cpm/well) 
as previously reported [1, 55]. Data represent the mean ± SD of 3 independent experiments 
performed in duplicate. The student t test was used to test the significance (P ≤ .05).
G. Tissue Histology Studies
Formalin-embedded tissue biopsy material obtained by laparoscopy of patient 2 (see “Case 
Reports”) was available for histology studies. Tissue was investigated microscopically after 
hematoxylin and eosin staining. Tissue was compared to ovarian tissues originating from 
one representative, age-matched normal girl, and one girl with Turner syndrome (TS).
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Figure 4. Multiple sequence alignment of affected CYP19A1 amino acid sequences from patients showing that 
all variants described in this report are conserved in higher primates. The valine 161 residue is well conserved 
across species and in some cases, a similar amino acid (isoleucine) was found (alligator, manakin, and turtle). 
The CYP19A1 proteins from human, chimpanzee, rhesus monkey and pig have an arginine at the position 264, 
whereas dog, cow, and mouse have a histidine, and rat, American alligator, golden-collared manakin, and turtle 
have glutamine at amino acid position 264. Considering the critical role of arginine 375 in heme binding, it was 
found to be conserved across species and no substitutions were identified in all the CYP19A1 sequences analyzed.
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2. Results
A. Phenotype-Genotype Characterization
We found novel CYP19A1 variants in 4 girls (Fig. 2) manifesting either at birth with atyp-
ical genitalia or puberty with poor breast development, clitoromegaly, abnormal menstrual 
bleeding, polycystic ovaries, and ovarian torsion (Fig. 3). Three mothers had signs of vir-
ilization during pregnancy (Table  2). Biochemical analysis revealed elevated androgens 
during pregnancy and in the neonate (in family 1), and in the adolescent girls with incom-
plete pubertal development (patients 3 and 4). Gonadotropins LH and FSH were elevated 
in the pubertal girls, whereas FSH was also abnormally high in the 3-year-old (Table 2). 
CAH due to 21-hydroxylase (and PORD) was ruled out by normal serum cortisol and 
17-hydroxyprogesterone levels (after adrenocorticotropin stimulation) in all patients, and 
with urinary steroid profiling on spot urine by gas chromatography–mass spectrometry in 
patient 2 (data not shown) [56].
Genetic analysis of patient 1 revealed a homozygote splice site deletion at the exon-
intron 9-3’ boundary (Fig. 2). Both consanguineous parents were heterozygote carriers of 
this variant. The 4 healthy brothers were not available for analysis. Characterization of this 
novel variant by minigene experiments revealed that the coded transcript contained the wt 
CYP19A1 sequence from exon 2 to exon 9, but then found a stop codon within intron 9 after 
addition of 6 aa due to the intronic splice site deletion that prevented correct splicing. The 
Figure 5. Multiple sequence alignment of CYP19A1 amino acid sequences from patients is 
shown. All the variants described in this report are conserved in higher primates as shown in 
Fig. 4.
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corresponding protein p.423_503del therefore lacked exon 10 completely and was only 426 
aa long compared to 503 aa of the wt protein.
In patient 2, compound heterozygote variants of the CYP19A1 gene were found. The 
previously described promoter c.–41C>T variant and a novel deletion/insertion in exon 5 
at c.603_608 led to a truncated aromatase protein that was predicted to have no enzyme 
activity (p.P154_delins) (25). Both parents were carriers of the p.P154_delins variant, and 
the mother carried, in addition, the c-41C>T variant (Fig. 2). Other family members were 
phenotypically normal and not available for genetic studies.
Patient 3 had 2 point mutations in exons 5 and 7, corresponding to c.624T>A (p.V161D) 
and c.932C>T (p.R264C) together with the promoter variant c.–41C>T. The consanguineous 
parents carried all these variants on 1 allele. Siblings were not affected and were not avail-
able for our study.
Finally, a homozygote point mutation in exon 9 was found in patient 4, c.1265C>T, 
p.R375C. Of the consanguineous parents, only the mother’s DNA was available for genetic 
analysis. She was found to carry the variant on 1 allele (Fig. 2).
B. Bioinformatic Characterization of the CYP19A1 Variants
Multiple-sequence alignment of affected CYP19A1 aa sequences from the patients is shown 
in Fig. 5. All mutations described in this report are conserved in higher primates (Fig. 4). 
An analysis of different aromatase sequences across species revealed valine 161 is well 
conserved across species, and in some cases, a similar aa (isoleucine) was found (alligator, 
manakin, and turtle). The V161D replacement was predicted to be less stable compared to 
wt CYP19A1, with a δ G value of –2.5 compared to wt protein. The substitution of valine 
161 for an aspartate introduces a buried charge and a hydrophilic residue in the core of the 
protein, which would cause reduced stability. Further, the helix 144 to 165 is also involved 
in protein stabilization, and the introduction of a charged residue is likely to cause reduced 
flexibility (Fig. 6A).
Figure 6. Structural location of CYP19A1 variants. A, Point mutations. Here a ribbons 
model of CYP19A1 protein colored in the rainbow from amino terminus (violet) to carboxy 
terminus (red) is shown and the bound substrate, androstenedione, and central heme mol-
ecule are depicted as stick models. Heme is ligated to the protein via cysteine 437 residue 
and forms the catalytic center of the CYP19A1 protein. The substitution of valine 161 for as-
partate introduces a buried charge and a hydrophilic residue in the core of the protein, which 
would cause reduced stability of the structure. The R264 residue on aromatase is surface 
exposed and located on the G helix of the CYP19A1 structure, which is part of the substrate 
access channel, and it has been widely reported to be flexible in cytochromes P450. The R375 
residue is involved in binding of heme propionate at the catalytic center of the CYP19A1, 
and its change to cysteine will lead to loss of heme binding and a nonfunctional protein. B, 
Identified deletion/insertion variations. The P423_H503delins mutation results in loss of 
critical amino acids in aromatase, including the heme ligating cysteine 437, and would, there-
fore, result in an inactive enzyme that would also be unstable and subject to degradation.
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R264C (rs700519) is a common polymorphic variant of CYP19A1 (CYP19A1*4). The 
R264C variant of CYP19A1 is present at a lower frequency in the European population, 
with a minor allele frequency (MAF) of 0.02 in the 1000 Genomes database but is more 
prevalent in the East Asian (MAF 0.17), South East Asian (MAF 0.24) and African (MAF 
0.18) populations. The R264 residue on the aromatase is on the surface and located on the G 
helix of the CYP19A1 structure (Fig. 6A), which is part of the substrate access channel, and 
it has been widely reported to be flexible in cytochrome P450 proteins. The R264 residue is 
also the central residue of a 3-arginine cluster that is part of a consensus sequence for sev-
eral kinases. Therefore, R264 may have a role both in the regulation of substrate access and 
posttranslational modifications of aromatase. Compared to the R263 position in aromatase, 
the R264 position is variable among species. The human, chimpanzee, rhesus monkey and 
pig have an arginine at the position 264; dog, cow, and mouse have a histidine, whereas the 
rat, American alligator, golden-collared manakin, and turtle have glutamine at position 
264. As part of the KRRR sequence (AA 262-265), lysine 262 and arginine 263 are conserved 
across species and no variations were found at these positions, and at position 265, either 
arginine or lysine is present across species (Fig. 4).
The R375 residue is involved in binding of heme propionate at the catalytic center of the 
CYP19A1, and its change to cysteine will lead to loss of heme binding, resulting in a non-
functional protein, which is consistent with a complete loss of activity observed for this mu-
tation (Figs. 6A and 7). Considering the critical role of arginine 375 in heme binding, it was 
found to be conserved across species, and no substitutions were identified in all CYP19A1 
sequences analyzed (Fig. 4).
The P154delins variant results in a truncated protein, which would be degraded (Fig. 8). 
The P423_H503delins mutation results in the loss of critical aa in aromatase, including the 
heme-ligating cysteine 437 (Fig. 6B), and would, therefore, result in an inactive enzyme 
that would also be unstable and subject to degradation.
C. In vitro Functional Characterization of the Identified CYP19A1 Variants
All CYP19A1 variants were tested in HEK293 cells for their ability to convert androstene-
dione to estrone using the tritiated water-release assay, as previously described [1, 57]. 
Both deletion/insertion variants and the 2 point variants p.V161D and p.R375C showed 
complete loss of aromatase activity (Fig. 9). By contrast, the p.R264C variation had similar 
aromatase activity as the wt CYP19A1. The double variant p.V161D and p.R264C, however, 
showed complete loss of function, like the p.V161D single variant. The functional effect of 
the promoter variant c.–41C>T on CYP19A1 expression has been previously described [25].
D. Histological Description of an Aromatase-Deficient Ovary in Infancy
Ovarian tissue for histological evaluation was available from patient 2. At age 3 years, his-
tology showed a normal-appearing ovary with normal-looking stroma and follicles on one 
side (Fig. 10A) compared to a healthy control ovary of the same age (Fig. 10C). By contrast, 
on the contralateral side, a streak gonad was identified macroscopically, with histological 
ovarian-like stroma without follicles (Fig. 10B) as found in typical TS (see age-matched pic-
ture of TS in Fig. 10D).
3. Discussion and Conclusion
There are only a few inborn errors of steroidogenesis that cause virilization of 46,XX 
individuals. The first group of disorders causes not only sex hormone disturbances but also glu-
cocorticoid deficiency, and is therefore called CAH. This group comprises 3β-hydroxysteroid 
dehydrogenase (HSD3B2), 21-hydroxylase (CYP21A2), and 11-hydroxylase (CYP11B1) 
deficiencies. The second group with normal glucocorticoid production comprises aroma-
tase deficiency (CYP19A1) and PORD, although in PORD stimulated cortisol production 
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is often also compromised [56, 58]. Furthermore, mothers virilize during pregnancy only 
with disorders of the second group, which affect the aromatization of fetal androgens by the 
fetal-placental unit.
All girls with CYP19A1 deficiency reported in this study had normal cortisol produc-
tion but suffered from androgen excess that manifested in utero (in 3 out of 4), at birth 
(in 2 to 3 out of 4), or puberty (in 1 or 2 out of 4) (see Table 2). Whether a detailed exam-
ination of the external genitalia would have revealed some atypical findings in patient 3 
at birth remains speculative. So far, most reported 46,XX individuals with aromatase de-
ficiency manifested at birth with moderate to severe virilization of the external genitalia 
Figure 7. Critical role of arginine 375 in heme binding. A and B, Structures of A, wild-type 
(WT), and B, R375C aromatase, shown as a ribbons model. The R375 residue is essential for 
the binding of heme at the catalytic center of the A, CYP19A1, and its change to B, cysteine, 
will lead to loss of heme binding, resulting in a nonfunctional protein. A complete loss of ac-
tivity was observed for the R375C variant. Therefore, the arginine 375 residue has a critical 
role in heme binding and activity of aromatase. These observations are further substantiated 
by the conservation of R375 residue in aromatase across species, and no substitutions were 
identified in all CYP19A1 sequences analyzed (Fig. 4). C and D, A close-up of heme ligation 
in aromatase C, WT and D, R375C. D, After the change of arginine 375 to cysteine, one of the 
bonds holding the heme in place, formed between the propionate group in heme and arginine 
375, is disrupted. The heme in aromatase, similar to other cytochrome P450 proteins, is held 
together by several bonds between the propionates of heme and arginines or histidine/tryp-
tophan groups located at the catalytic center. Disruption of these linkages will lead to an un-
stable heme-binding site in aromatase and loss of heme, which would cause a nonfunctional 
protein. All the critical arginines (115, 145, and 375), as well as tryptophan 141 and cysteine 
427, are conserved across species (Fig. 4), and no variation is observed at any of these places, 
confirming the importance of these amino acids in the function of aromatase.
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(Prader III-V) (n = 25/34; Table 1). This has led to male sex assignment at birth in three 
46,XX individuals, 2 of whom were reassigned to the female sex after diagnosis in child-
hood. Signs of virilization during pregnancy have been described in about half of mothers 
carrying an affected child. During infancy and childhood, ovarian cysts were noted in sev-
eral and were either symptomatic or seen by imaging studies. At puberty, incomplete devel-
opment with poor breast development, menstrual cycle anomalies, polycystic ovaries, and 
signs of androgen excess (eg, hirsutism, acne, enlarged clitoris) are typically due to estrogen 
deficiency and elevated androgens. Late diagnosis at pubertal age is described in less than 
one-third of reported 46,XX aromatase-deficient female patients. Of the 15 reported female 
individuals older than pubertal age, 4 showed no signs of spontaneous puberty, 6 had incom-
plete development, and only 5 spontaneously reached Tanner 5 (Table 1).
By contrast, affected 46,XY individuals typically present at around age 20 to 30 years 
with extremely tall stature due to failure of growth arrest. Only if the diagnosis is known 
in the family or maternal virilization during pregnancy raised suspicion, may diagnosis be 
Figure 9. Aromatase activity of identified CYP19A1 variants. Variants were built into the 
mammalian expression vector containing wt CYP19A1 cDNA. HEK293 cells were transiently 
transfected with wt and variant CYP19A1 plasmids, and aromatase activity was assessed by the 
tritiated water-release assay testing conversion of androstenedione to estrone. Compared to wt, 
all variants except p.R264C showed complete loss of activity. *P value is less than or equal to .05.
Figure 8. The P154delIns protein variant lacks most of the critical residues of aromatase re-
quired for catalytic function because of truncation (shown in magenta). Such a small protein, 
without functionally important structural features, will be misfolded and degraded, leading 
to a complete loss of aromatase activity.
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made earlier in boys. We also suspect that the diagnosis is less often made in boys than girls 
because the clinical picture is less remarkable and manifests only in early adulthood when 
genetic disorders are less suspected; this may be evidenced by fewer reported cases of male 
patients in the literature (n = 13/47; Table 1), which does not reflect the autosomal recessive 
inheritance and the true incidence.
Owing to enlarged ovaries with cysts or polycystic ovaries, torsion of an ovary is a fre-
quent complication that may occur early in life. This complication can be prevented by 
very low-dose estrogen replacement starting early in life [34, 59]. At puberty, sex hormone 
replacement therapy is required to allow for complete pubertal development and normal 
menstrual bleeding. So far no successful pregnancy has been described in a woman with aro-
matase deficiency. However, it is not excluded that this could be possible with the help of as-
sisted reproduction, as recently demonstrated in a woman with 17-hydroxylase (CYP17A1) 
deficiency, a steroid enzyme essential for the production of all sex hormones [60]. Histologic 
investigations of ovarian tissue of female patients carrying CYP19A1 variants are scarce. 
We had a chance to investigate ovarian biopsy material in patient 2 and found a normal-
looking ovary on one side and a streak gonad on the other. In the literature, ovaries are 
often reported to look normal or only slightly abnormal in size by imaging studies in very 
young girls, although smaller cysts may be found very early when specifically searched for. 
Imaging studies later during infancy and childhood mostly reveal abnormal ovarian cysts, 
which may resemble the picture of a polycystic ovary by the age of puberty (Table 1). This 
resulted in ovarian torsion in several cases, even at a very young age.
Furthermore, streak ovaries or absent/nonvisualized ovaries have been reported with 
CYP19A1 deficiency [17, 27, 30]. Thus it appears that aromatase deficiency might lead 
Figure 10. Histology of an ovary originating from a toddler with aromatase deficiency. A, 
Hematoxylin and eosin (HE) histology picture of one ovary of patient 2 showing a normal 
ovary with normal stroma and follicles. B, HE histology of the contralateral ovary showing a 
streak gonad without follicles. C, HE picture of a normal, age-matched ovary. D, HE picture 
of a typical Turner syndrome streak ovary, age matched.
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to an earlier destruction of the ovary than with other steroid biosynthetic disorders 
such as lipoid CAH due to steroidogenic acute regulatory protein deficiency. In STAR 
deficiency, lipid overload destroys the gonad over time and a PCOS-like phenotype is 
not characteristic [61]. Studies of ovary development have shown that concerted activity 
of aromatase (as well as other steroidogenic enzymes such as HSD17s and HSD3B2), 
steroid hormones (eg, estrogens and progesterone), and gonadotropins (eg, FSH) is es-
sential for normal primordial follicle pool development during fetal life as well as for 
normal follicle maturation and ovulation in the adult ovary [62]. In the human fetal 
ovaries, expression of aromatase and estrogen receptors is upregulated in the second 
trimester when primordial folliculogenesis is fully active [63]. By contrast, mice lacking 
aromatase activity develop ovaries with diminished oocyte density [64, 65]. In addi-
tion, coordinated action of estrogens and FSH are also crucial for the proper timing 
of folliculogenesis [66]. In aromatase deficiency lack of estrogens results in abnormal 
gonadotropin feedback, which affects follicle growth in the ovaries. It has been shown 
that for the formation of (poly-)cystic ovaries elevated FSH plays a critical role [67, 68]. 
Overall, these facts from the literature may explain the ovarian phenotypes (both streak 
gonads and polycystic ovaries) seen with aromatase deficiency. Based on this knowledge 
and clinical experience (eg, [34]) (preventive) treatment of polycystic ovaries with es-
trogen replacement normalizing FSH should be advised in all patients with aromatase 
deficiency.
Human CYP19A1 variants described so far are summarized in Table  1. They span 
over all exons and comprise all types of genetic variations, as shown in Fig.  1. The 
genotype-phenotype correlation seems doubtful, but structure-function prediction has 
revealed consistent results with few exceptions. We found novel CYP19A1 variants in 
4 affected girls. These variants were all predicted to severely affect enzyme activity, and 
functional tests confirmed this prediction. Novel deletion-insertion variants of CYP19A1 
found in patients 1 and 2 received the label “pathogenic” when characterized according to 
American College of Medical Genetics and Genomics (ACMG) standards and guidelines 
[69]. In  silico structure-function studies of the identified CYP19A1 variations showed 
loss of the heme-binding site due to the R375C variation and was predicted to cause 
a loss of function. In the case of the V161D variant, a loss of protein stability leading 
to degradation was predicted. This novel point mutation found in patient and family 3 
is likely pathogenic according to ACMG characterization and was found in combina-
tion with known variants –41C>T and R264C. Variants R264C and R375C have been 
described previously [18, 70]. In line with our results, R375C was found to cause a com-
plete loss of function. Although in silico structural prediction could not provide a clear 
analysis for the R264C variant, we found that the R264C variant showed activity similar 
to wt CYP19A1. The R264C variation is known in the literature as a polymorphism of 
CYP19A1, which seems common in Southeast Asia [70]. However, this CYP19A1 variant 
may affect enzyme function when it is present in combination with specific variants of 
cytochrome P450 oxidoreductase (POR), as reported in a recent study [70]. Partial loss 
of function of aromatase activity has been found with CYP19A1 variant R192H [1] and 
with several POR variants [56, 71-73]. Patients carrying these mutations manifest with 
variable degrees of virilization either at birth or puberty.
In summary, we describe clinical, genetic, and functional implications of novel CYP19A1 
variants identified in 4 girls originating from Africa and India. CYP19A1 deficiency seems 
to cause maternal virilization in more than 50% of pregnancies and manifest with some de-
gree of ambiguous genitalia in more than 70% of 46,XX newborns. Additionally, about 80% 
of affected girls are unable to enter or complete puberty spontaneously and need hormonal 
replacement therapies. The ovary with aromatase deficiency develops a polycystic ovary 
phenotype  in most cases, but streak gonads are also seen. Normal aromatase activity in 
concerted action with other steroid enzymes and hormones as well as gonadotropins seem 
essential for proper ovarian follicle pool development during fetal life and for follicle matu-
ration and ovulation during the reproductive years.
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